AOD-9604 vs Ipamorelin: Which Is Better for Fat Loss?
Should I use AOD-9604 or ipamorelin for fat loss?
Neither, if fat loss is the goal. Both score 2.0 on body composition, which is the row a vendor sells them on. AOD-9604 scores 4.6 overall and its only controlled human weight-loss program failed against placebo. Ipamorelin scores 6.2 and its only completed human efficacy trial also failed. Two peptides, zero positive human trials.
- Body composition is 2.0 against 2.0. The shared use case both products are sold on is the one where neither scores above the floor.
- AOD-9604's developer ran the controlled human weight-loss program and it failed to beat placebo. There is no positive human efficacy trial for it in the literature.
- Ipamorelin's only completed human efficacy trial was a 114-person phase 2 in postoperative ileus. It missed its primary endpoint at p=0.15 and development stopped.
- Ipamorelin scores 6.2 to AOD-9604's 4.6, and the gap is receptor selectivity plus a real mechanism, not results. It does pulse growth hormone. AOD-9604's fat-loss case is rodent only.
- AOD-9604 costs more for less: $72 to $99 a month against $25 to $60. Both are gray-market research-chemical estimates, not pharmacy prices.
- Both are prohibited by WADA at all times, and both need a lot-matched third-party certificate of analysis. Henninge 2014 found AOD-9604 inside seized unknown peptide preparations.
- Active or hormone-sensitive cancer rules out both. Sigalos and Pastuszak 2018 called for long-term secretagogue safety data including cancer endpoints, and that data still does not exist.
At a Glance
AOD-9604
- Efficacy 1.4
- Breadth 1.6
- Evidence 1.8
- Speed 2.0
- Durability 2.0
- Bioindividuality 2.0
- Safety Risk 1.8
- Side Effects 1.6
- Cost 2.8
- Effort 3.0
- Opportunity Cost 3.5
- Dependency 1.8
- Reversibility 1.6
- Body Composition
- Bone Joint
- Metabolic Health
- Recovery Repair
hGH 176-191 lipolytic fragment. BioHarmony 4.6, neutral.
Ipamorelin
- Efficacy 3.3
- Breadth 3.3
- Evidence 3.3
- Speed 3.2
- Durability 2.4
- Bioindividuality 3.3
- Safety Risk 1.8
- Side Effects 1.6
- Cost 2.6
- Effort 3.0
- Opportunity Cost 2.2
- Dependency 2.6
- Reversibility 1.6
- Sleep Quality
- Recovery Repair
- Bone Joint
- Injury Recovery
Selective ghrelin-receptor growth hormone secretagogue. BioHarmony 6.2, worth trying.
Head-to-Head Verdict
| Use Case | Winner | Rationale |
|---|---|---|
| Body Composition | Tie | Both 2.0, and that is the honest headline. AOD-9604's fat-loss evidence is Heffernan 2000 and Ng 2000, both rodent, and the human program its developer ran failed against placebo. Ipamorelin raises growth hormone but has no completed body-composition trial in humans. A tie at 2.0 is not a draw between two options, it is a no. |
| Metabolic Health | AOD-9604 | AOD-9604 2.0 against ipamorelin's 1.6, the only row the lower-scoring peptide wins. The reason is what AOD-9604 does not do: Ng 2000 showed it does not bind the growth hormone receptor, does not induce cell proliferation and caused no hyperglycemia in mice. Ipamorelin activates the GH and IGF-1 axis, which is why uncontrolled diabetes sits on its contraindication list. |
| Recovery Repair | Ipamorelin | Ipamorelin 2.4 against AOD-9604's 1.8, the widest gap in the matrix and still a low number. Ipamorelin's case is anti-catabolic and animal-based: Aagaard 2009 cut glucocorticoid-induced hepatic nitrogen wasting by about 20% in rats, and Malmlof 1999 showed methylprednisolone did not block its growth hormone release. AOD-9604 has no recovery mechanism at all. |
| Bone Joint | Ipamorelin | Ipamorelin 2.2 against 2.0, effectively a coin flip on paper but with more behind it. Three rodent studies support ipamorelin here: Johansen 1999 on longitudinal bone growth, Svensson 2000 on bone mineral content through bone size rather than density, and Andersen 2001 on countering glucocorticoid-induced loss. AOD-9604's joint claim rests entirely on Kwon 2015, one rabbit model. |
| Muscle Growth | Ipamorelin | Ipamorelin 1.9 against AOD-9604's 1.5. Ipamorelin at least has a plausible route through GH and IGF-1, and Sinha 2020 reviews body composition in the secretagogue class, though the best data in that review comes from other secretagogues rather than from ipamorelin. AOD-9604 explicitly does not bind the growth hormone receptor, so it has no anabolic pathway by design. |
| Injury Recovery | Ipamorelin | Ipamorelin 2.1 against 1.8. Same rodent anti-catabolic story as the recovery row, and the same caveat: nothing here is human. Patel 2026, an orthopaedics review, lists AOD-9604 among growth-hormone-secretagogue-class adjuncts and documents the current absence of clinical trials. That absence is the finding. |
| Energy | Ipamorelin | Ipamorelin 2.0 against AOD-9604's 1.6. Ipamorelin's route is the slow-wave sleep effect: Weikel 2003 infused ghrelin in 7 men and increased slow-wave sleep, and ipamorelin acts on the same GHS-R1a receptor. That is a proxy in seven people, not an energy trial. AOD-9604 has no such route. |
| Healthspan | Tie | AOD-9604 1.5, ipamorelin 1.7, both near the floor. Neither has human longitudinal data of any kind, and the secretagogue class has an open safety question rather than a healthspan case: Sigalos and Pastuszak 2018 called for long-term data including cancer endpoints. Nothing here supports taking either one for aging. |
| Longevity | Tie | AOD-9604 1.5, ipamorelin 1.7, and the honest reading is that these scores are placeholders for an absence. Grogan 2026 groups AOD-9604 with unapproved gray-market peptides that have favorable animal data, scarce human safety data and a social-media-amplified placebo caveat. That sentence covers both sides of this page. |
| Anti Inflammatory | Tie | AOD-9604 1.5, ipamorelin 1.4, inside the noise and both at the floor. AOD-9604's only anti-inflammatory-adjacent result is the Kwon 2015 rabbit cartilage model, which used intra-articular injection with hyaluronic acid rather than the subcutaneous protocol people actually run. Ipamorelin has nothing here. |
| Endurance Cardio | Tie | Both 1.4, the lowest shared row on the page and an exact tie. Neither peptide has an endurance mechanism, an endurance trial or an endurance claim in its own report. Both are prohibited by WADA at all times anyway, so a competing athlete cannot use either regardless of what the score says. |
Cost Comparison
| Intervention | Monthly Cost | Notes |
|---|---|---|
| AOD-9604 | $72 to $99 | ESTIMATE, priced 2026-09-08, research-chemical channel. Five milligram vials run about $40 to $55 depending on vendor, and a 300 mcg daily protocol consumes 9 mg over 30 days, roughly 1.8 vials. Add a lot-matched third-party HPLC certificate to that figure, because there is no approved human product and the vial is the only thing standing between you and an unknown powder. |
| Ipamorelin | $25 to $60 | ESTIMATE, priced 2026-09-07, research-chemical channel. A 5 mg vial at $25 to $50 yields 33 to 50 doses at 100 to 150 mcg, which is 1.1 to 1.7 months, so roughly $18 to $45 a month plus $8 to $13 of bacteriostatic water, syringes and swabs. Compounded telehealth supply runs higher, in the $40 to $90 range the report cites. |
| The difference | AOD-9604 costs about $40 a month more for the weaker case | The cheaper peptide is also the better-supported one, which is unusual and worth stating plainly. AOD-9604 runs roughly $40 a month more than ipamorelin, about $480 a year, for a compound whose only controlled human weight-loss program failed.Neither figure includes the certificate of analysis, which is not optional on a gray-market vial and is a real recurring cost per lot. Factor that in and the honest comparison is a few hundred to a thousand dollars a year against two source reports that score body composition at 2.0 each. |
When to Switch
Their assessment windows differ enough to matter. Ipamorelin's is 12 weeks with a first noticeable change at about one week, driven mostly by sleep. AOD-9604's is 8 weeks with a first change at four, and both of its onset figures are marked estimated rather than extracted, so treat them as guesses rather than measurements.
Switching from AOD-9604 to ipamorelin is the more defensible move of the two, and the reason is not that ipamorelin works better for fat loss. It is that ipamorelin has a real, characterized mechanism: Raun 1998 established it as the first selective growth hormone secretagogue with no significant ACTH or cortisol rise.
AOD-9604's mechanism is a rodent lipolysis story that Heffernan 2001 partly falsified, showing the effect is not directly mediated by the beta-3 adrenergic receptor. Ipamorelin also costs about $40 a month less.
The switch worth making is off both. Both source reports say the same thing in different words: no positive human efficacy trial exists for AOD-9604, and ipamorelin's single completed human efficacy trial (Beck 2014, n=114) missed its primary endpoint at p=0.15, after which development stopped.
If fat loss is the goal, both source reports name the GLP-1 and dual-agonist drugs as the comparators that carry outcome data. If you keep either one, run it as an experiment with a defined stop date, not as a protocol.
Who Should Pick What?
Anyone whose goal is losing body fat
Tie
Neither. Body composition scores 2.0 on both. AOD-9604's developer ran the controlled human weight-loss program and it failed against placebo. Ipamorelin has no completed body-composition trial. Both reports name the incretin drugs as the comparators with actual outcome data, and those are prescription products with trials behind them.
Someone already holding AOD-9604 vials and deciding whether to continue
Ipamorelin
If you are going to run a gray-market growth hormone peptide anyway, ipamorelin is the better version of that decision: a characterized selective mechanism (Raun 1998), $40 a month cheaper, and better scores on seven of the twelve shared rows. That is a harm-reduction answer, not a recommendation to start.
Person with uncontrolled diabetes or blood-sugar concerns
AOD-9604
Ipamorelin is out. Uncontrolled diabetes is on its contraindication list because it activates the GH and IGF-1 axis. AOD-9604 does not bind the growth hormone receptor, and Ng 2000 found no hyperglycemia in mice. That is the narrow case where the 4.6-scoring peptide beats the 6.2-scoring one, and it still is not a reason to take it.
Competing athlete in a tested sport
Tie
Neither, and this one is not a judgment call. WADA prohibits growth hormone secretagogues at all times under S2, which covers ipamorelin, and Stier 2014 documents AOD-9604's WADA ban directly. In-competition tested sport is on both contraindication lists. A gray-market vial with an unverified contents profile makes the risk worse, not better.
Anyone with active or hormone-sensitive cancer, or a cancer history
Tie
Neither. Active or hormone-sensitive cancer is contraindicated on both, and AOD-9604 extends it to any cancer history. Sigalos and Pastuszak 2018 reviewed secretagogue safety and specifically called for long-term data including cancer endpoints, which does not exist. GH and IGF-1 signaling is the wrong axis to push on with an open question like that.
Person with a joint problem hoping for cartilage repair
Tie
Neither, and the AOD-9604 joint claim deserves a direct correction. It comes from Kwon 2015, a single rabbit collagenase osteoarthritis model using intra-articular AOD-9604 with hyaluronic acid. That is a different species, a different injection site and a co-administered drug. Patel 2026 documents the absence of clinical trials in this space.
Someone whose actual complaint is poor sleep
Ipamorelin
If anything on this page is going to produce a noticeable change, it is this, and the evidence is still thin. Ipamorelin's first noticeable effect lands at about one week and the mechanism is slow-wave sleep promotion through GHS-R1a. The supporting human data is Weikel 2003, a ghrelin infusion in seven men. Cheaper and safer sleep tools exist.
Anyone unwilling to pay for a per-lot certificate of analysis
Tie
Neither, without exception. Both are gray market with purity verification required, and both source reports name an unverified vial as a contraindication in its own right. Henninge 2014 found AOD-9604 inside seized unknown peptide preparations. Without a lot-matched third-party HPLC result you do not know what is in the vial.
Research Highlights
-
Mechanism Difference
These two peptides work on opposite sides of the growth hormone system, and one of them deliberately avoids it. AOD-9604 is the C-terminal 176-191 lipolytic fragment of human growth hormone. Ng 2000 showed it stimulates fat breakdown in rodents without binding the growth hormone receptor, which is why it avoids the IGF-1 and blood-sugar effects of full hGH and also why it has no anabolic pathway.Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist that pulses pituitary growth hormone without meaningfully raising ACTH, cortisol or prolactin. Raun 1998 established that selectivity, and it is the entire case for ipamorelin over GHRP-2 and GHRP-6. One avoids the GH axis, the other is the GH axis.
-
Safety Comparison
Neither is safe in the sense buyers mean, because neither has been studied long enough in humans to know. Both exclude active or hormone-sensitive cancer, pregnancy, breastfeeding, and in-competition tested sport under WADA's blanket prohibition on growth hormone secretagogues.Both require a third-party certificate of analysis, and both source reports treat an unverified vial as a contraindication in itself.Their specific risks differ. Ipamorelin adds uncontrolled diabetes, congestive heart failure and critical illness because it activates the GH and IGF-1 axis. AOD-9604 adds any cancer history and documented supply contamination: Henninge 2014 identified it inside unknown peptide preparations seized by Belgian authorities.
-
Cost Comparison
Ipamorelin runs about $25 to $60 a month through the research-chemical channel, from 5 mg vials at $25 to $50 giving 33 to 50 doses at 100 to 150 mcg, plus supplies. AOD-9604 runs about $72 to $99, because a 300 mcg daily protocol consumes 9 mg over 30 days, roughly 1.8 vials. Both are estimates, not measured prices.The cheaper peptide is also the better-supported one here, which almost never happens. AOD-9604 costs roughly $480 a year more than ipamorelin for a compound whose only controlled human weight-loss program failed. Neither figure includes the per-lot certificate of analysis, which on a gray-market vial is a real recurring cost.
-
Editorial Verdict
Ipamorelin scores 6.2 and AOD-9604 4.6, and the gap is mechanism quality rather than results. Ipamorelin is a characterized selective growth hormone secretagogue with clean receptor pharmacology. AOD-9604 is a growth hormone fragment whose rodent lipolysis story was partly falsified by Heffernan 2001, which showed the effect is not directly mediated by the beta-3 adrenergic receptor.For the use case that sells both, the answer is neither. Body composition scores 2.0 on each. AOD-9604's controlled human weight-loss program failed against placebo, and ipamorelin's only completed human efficacy trial (Beck 2014, n=114 in postoperative ileus) missed its primary endpoint at p=0.15, after which development stopped.
-
Durability
Durability scores are 2.0 for AOD-9604 and 2.4 for ipamorelin, both low and both inferred rather than measured, because no human trial has followed either compound past cessation. Ipamorelin has a further wrinkle: Jimenez-Reina 2002 found chronic dosing altered somatotroph response in young female rats, which is a tolerance question nobody has answered in people.Assessment windows are 12 weeks for ipamorelin and 8 for AOD-9604, and both of AOD-9604's onset figures are marked estimated rather than extracted from trial data. Any decision you make about either one at the end of a window is a subjective judgment, not a readout.
Frequently Asked Questions
- Which one is better for fat loss, AOD-9604 or ipamorelin?
- Neither. Both score 2.0 on body composition, the lowest meaningful score either report gives. AOD-9604's developer ran a controlled human weight-loss program that failed to beat placebo, and no positive human efficacy trial exists for it. Ipamorelin has never completed a body-composition trial in humans at all.
- Does AOD-9604 actually work?
- In rodents, for lipolysis. Heffernan 2000 cut body-weight gain by more than half over 19 days in obese Zucker rats and Ng 2000 raised fat oxidation in mice. In humans, no. The developer's controlled weight-loss program failed against placebo, and Heffernan 2001 showed the proposed beta-3 adrenergic mechanism is not the direct route.
- Is ipamorelin proven in humans?
- Its receptor pharmacology is, its clinical effect is not. Raun 1998 established it as the first selective growth hormone secretagogue with no significant ACTH or cortisol rise. Its only completed human efficacy trial, Beck 2014 in 114 postoperative ileus patients, missed its primary endpoint at p=0.15 and development stopped there.
- Why does ipamorelin score higher if both failed their trials?
- Because scoring weights mechanism quality and breadth, not just outcomes. Ipamorelin is 6.2 against AOD-9604's 4.6 on a characterized selective mechanism, better animal breadth, and cheaper safer access, and it beats AOD-9604 on seven of the twelve shared use cases. A higher score on this pair means a better bet, not a good one.
- Are these legal, and can I compete while using them?
- Neither has an approved human product. Both are supplied through research-chemical vendors or compounding-adjacent telehealth. WADA prohibits growth hormone secretagogues at all times under S2, which covers ipamorelin, and Stier 2014 documents AOD-9604's ban. In-competition tested sport is a contraindication on both lists.
- How much does each cost?
- Ipamorelin runs about $25 to $60 a month at 100 to 150 mcg from 5 mg vials, plus supplies. AOD-9604 runs about $72 to $99, because 300 mcg daily consumes 9 mg over 30 days. Both are gray-market estimates priced September 2026. Neither includes the per-lot third-party certificate of analysis, which is not optional.
- Can AOD-9604 repair my joints?
- There is no human evidence for that. The claim traces to Kwon 2015, one rabbit collagenase osteoarthritis model using intra-articular injection alongside hyaluronic acid. Different species, different route, and a co-administered drug. Patel 2026 documents the absence of clinical trials here. Its bone and joint subrating is 2.0.
- Who should not use either one?
- Anyone with active or hormone-sensitive cancer, anyone pregnant or breastfeeding, anyone under 18, and anyone competing in a tested sport. Ipamorelin adds uncontrolled diabetes, congestive heart failure and critical illness. AOD-9604 adds any cancer history. Both add any vial without a lot-matched third-party certificate of analysis.
Evidence Sources
- Preclinical Heffernan 2000, Endocrinology: oral AOD9604 and body-weight gain in obese Zucker rats (2000) Cut body-weight gain by more than half over 19 days while raising adipose lipolysis, with no harm to insulin sensitivity. Rodent only.
- Preclinical Ng 2000, Diabetes Obesity and Metabolism: AOD9604 mechanism in mice (2000) Reduced body-weight gain and raised fat oxidation, did not bind the growth hormone receptor, did not induce cell proliferation, no hyperglycemia.
- Preclinical Heffernan 2001, Journal of Endocrinology: AOD9604 and the beta-3 adrenergic receptor (2001) The lipolytic action is not mediated directly through the beta-3 adrenergic receptor, falsifying the beta-3 agonist shorthand.
- Preclinical Kwon 2015, Journal of Veterinary Science: intra-articular AOD9604 in a rabbit osteoarthritis model (2015) Reduced cartilage degeneration and lameness with hyaluronic acid co-administration. A single rabbit study, and the entire basis for the joint-repair claim.
- Review Stier 2014, Drug Testing and Analysis: AOD9604 regulatory and analytical review (2014) Marketed to mimic lipolysis without diabetogenic effects, sold on the internet, banned by WADA, and detected in confiscated vials.
- Forensic Henninge 2014, Drug Testing and Analysis: AOD9604 in seized peptide preparations (2014) Identified inside unknown peptide preparations seized by Belgian authorities, documenting the gray-market contamination and identity risk.
- Review Grogan 2026, Sports Medicine: gray-market peptide review (2026) Groups AOD-9604 with unapproved gray-market peptides that have favorable animal data, scarce human safety data and a social-media-amplified placebo caveat.
- Regulatory FDA 2024 briefing materials for the Pharmacy Compounding Advisory Committee (2024) FAERS and literature searched through January 2024 with no adverse-event reports for AOD-9604. Reviewed for the 503A bulks list.
- Preclinical Raun 1998, European Journal of Endocrinology: ipamorelin selectivity (1998) The first selective growth hormone secretagogue, with no significant ACTH or cortisol rise. The defining characterization.
- RCT Beck 2014, International Journal of Colorectal Disease: ipamorelin phase 2 in postoperative ileus (2014) n=114. Failed its primary endpoint at p=0.15 and development was discontinued. The only completed human efficacy trial.
- Preclinical Johansen 1999, Growth Hormone and IGF Research: ipamorelin and longitudinal bone growth (1999) Induced longitudinal bone growth in rats.
- Preclinical Svensson 2000, Journal of Endocrinology: ipamorelin and bone mineral content (2000) Increased bone mineral content in adult female rats via bone size rather than density.
- Preclinical Andersen 2001, Growth Hormone and IGF Research: ipamorelin against glucocorticoid-induced bone loss (2001) Counteracted glucocorticoid-induced decrease in bone formation in adult rats.
- Preclinical Aagaard 2009, Growth Hormone and IGF Research: ipamorelin and nitrogen wasting (2009) Reduced glucocorticoid-induced hepatic nitrogen wasting by about 20% in rats.
- Review Sigalos and Pastuszak 2018, Sexual Medicine Reviews: growth hormone secretagogue safety (2018) Class safety and efficacy review calling for long-term safety data including cancer endpoints.
- RCT Weikel 2003, American Journal of Physiology: ghrelin infusion and slow-wave sleep (2003) Ghrelin infusion increased slow-wave sleep in 7 men. A receptor proxy for ipamorelin, which acts on the same GHS-R1a.
- Review Sinha 2020, Translational Andrology and Urology: secretagogues and body composition (2020) Body-composition context for the secretagogue class. The best data comes from secretagogues other than ipamorelin.
- Preclinical Jimenez-Reina 2002, Histology and Histopathology: chronic ipamorelin and somatotroph response (2002) Chronic dosing altered somatotroph response in young female rats. An unanswered tolerance question in humans.
- Review Patel 2026, orthopaedics review: growth hormone secretagogue class adjuncts (2026) Lists AOD-9604 as a secretagogue-class adjunct and documents the current lack of clinical trials.
- Regulatory WADA 2026 Prohibited List (2026) Growth hormone secretagogues are prohibited at all times under S2, covering ipamorelin.
Glossary
Quick reference for the medical and technical terms used in this comparison.
- hGH 176-191 Human Growth Hormone Fragment 176-191
- The C-terminal lipolytic fragment of growth hormone that AOD-9604 is. It reproduces the fat-breakdown region without the receptor binding, which is both its selling point and why it has no anabolic effect.
- GHS-R1a Growth Hormone Secretagogue Receptor 1a
- The ghrelin receptor. Ipamorelin activates it selectively, which is how it pulses growth hormone without raising ACTH, cortisol or prolactin the way GHRP-2 and GHRP-6 do.
- IGF-1 Insulin-Like Growth Factor 1
- The downstream hormone growth hormone acts through. Ipamorelin raises it, which is why uncontrolled diabetes is contraindicated. AOD-9604 does not, by design.
- COA Certificate of Analysis
- A lot-matched third-party HPLC or mass spectrometry result confirming what is in the vial. Required for both peptides, and a recurring cost neither price estimate includes.
- WADA S2 WADA Prohibited List Section S2
- The peptide hormones and growth factors category, prohibited at all times in and out of competition. It covers growth hormone secretagogues including ipamorelin.
- Lipolysis Lipolysis
- The breakdown of stored fat into fatty acids. AOD-9604's whole case rests on raising it in rodents, and Heffernan 2001 showed the route is not the beta-3 adrenergic receptor people cite.
- 503A 503A Bulks List
- The FDA list of substances compounding pharmacies may legally use. AOD-9604 was reviewed for it in 2024, which is a regulatory step rather than an approval.
- FAERS FDA Adverse Event Reporting System
- The federal adverse-event database. FDA found no AOD-9604 reports through January 2024, which reflects low reported use rather than demonstrated safety.
